ReviewJournal of translational medicine2026
Cross-reactive tissue-resident memory T lymphocytes-concepts, evidence, and open questions.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut-derived memory T cells: key mediators of neuroinflammation via the gut-brain axis.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTissue-resident memory T (Trm) cells have emerged as a distinct lymphocyte lineage that provides rapid, frontline immune surveillance in peripheral tissues while also contributing to durable systemic immunity. A critical and evolving aspect of Trm cell biology is their inherent cross-reactivity-the ability of a single T cell receptor (TCR) to recognize and respond to multiple related or unrelated antigens beyond its primary target. MAIN BODY: This review synthesizes current knowledge on the dual roles of cross-reactive Trm cells, which can mediate broad protection against heterologous infections and cancers but may also precipitate or exacerbate autoimmune pathology. We first address the developmental origins, tissue-specific distribution (from barrier surfaces to internal organs, including the central nervous system and bone marrow niches), and key functions that define the Trm population. A central focus is placed on the mechanistic basis of TCR cross-reactivity, comparing and contrasting its regulation in circulating memory T cells versus Trm cells. We delve into how tissue-specific signals, particularly local cytokine milieus and epigenetic reprogramming such as demethylation imprints, shape the functional avidity and antigenic breadth of Trm cell responses. Finally, we discuss emerging therapeutic strategies designed to either harness the protective cross-reactivity of Trm cells for next-generation vaccines and immunotherapies or to restrain its detrimental potential in autoimmune and inflammatory diseases.
conclusionsTrm cells are powerful immune sentinels whose TCR cross-reactivity enables broad protection but also risks autoimmunity. Understanding these precise rules is key to developing Trm-based immunotherapies against cancer and infections while avoiding autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.